Document:

trtc_ex41.htm

EXHIBIT 4.1
  
 THIS NOTE HAS NOT (AND ANY SHARES OF STOCK ISSUABLE UPON THE TRIGGERING OF AN EVENT OF DEFAULT MAY NOT HAVE) BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. NEITHER THIS NOTE NOR ANY SHARES OF STOCK ISSUABLE UPON THE TRIGGERING OF AN EVENT OF DEFAULT MAY BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THIS NOTE OR SHARES OF STOCK ISSUABLE UPON DEFAULT UNDER THIS NOTE UNDER SUCH ACT UNLESS SUCH REGISTRATION IS NOT REQUIRED PURSUANT TO A VALID EXEMPTION THEREFROM UNDER THE ACT.
  
 Terra Tech Corp.
  
 Promissory Note
  
  	 Face Amount: $1,000,000.00 
	 March 4, 2019

	  
	 New York, NY

  
 FOR VALUE RECEIVED, the undersigned Terra Tech Corp., (the “Borrower”), promises to pay to the order of __________, its successors or assigns (the “Lender”), ONE MILLION DOLLARS ($1,000,000) (the “Face Amount”) by the earlier of April 4, 2019 (the “Maturity Date”), upon the closing of a financing with gross proceeds that are equal to or greater than $1,000,000 in accordance with the terms hereof, together with interest, as provided herein.
  
 Interest at the simple rate of one and one-half percent (1.50%) per month, calculated on the basis of a 360-day year of twelve 30-day months, until the Maturity Date or repayment is made as provided herein, and any other amounts due hereunder are payable in lawful money of the United States of America to the Lender. Interest may be paid in cash at the Maturity Date, which includes the maturity on the closing of a financing equal to or greater than $1,000,000. In the event that this Note is outstanding for less than 30-days, interest due thereon for such period shall be guaranteed as if the Note had been outstanding for a full 30 days.
  
 Section 1. Maturity. The Face Amount, along with the interest accrued thereon, shall be repaid in cash at the Maturity Date, unless repaid earlier in connection with the closing of a financing with gross proceeds that are equal to or greater than $1,000,000. 
  
 Section 2. Repayment. This Note may be prepaid in whole or in part at any time and from time-to-time upon three (3) prior business days’ written notice, without penalty. Such repayment shall satisfy Borrower’s obligations pursuant to this Note in full and this Note shall be of no further force and effect.
  
 Section 3. Transferability. This Note and any of the rights granted hereunder are freely transferable or assigned by Lender, in whole or in part, in its sole discretion; provided, that the Lender provides notice to the Borrower of its transfer or assignment. 
  
  	 
	1
	 
 
	 

  
 Section 4. Event of Default.
  
 (a) In the event that any one of the following events shall occur (whatever the reason and whether it shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order, rule or regulation of any administrative or governmental body), it shall be deemed an Event of Default:
  
 (i) Any default in the payment of the principal, interest on, or other charges in respect of this Note, or any other note issued by the Borrower, as and when the same shall become due and payable;
  
 (ii) Borrower shall fail to observe or perform any other material covenant, agreement or warranty contained in, or otherwise commit any breach or default of any provision of this Note or any other agreement between the Borrower and the Lender; 
  
 (iii) There shall be a breach of any of the representations and warranties set forth in this Note or any transaction document executed contemporaneously herewith; or
  
 (iv) Borrower, shall commence, or there shall be commenced against Borrower any applicable bankruptcy or insolvency laws as now or hereafter in effect or any successor thereto, or Borrower commences any other proceeding under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to Borrower or there is commenced against Borrower any such bankruptcy, insolvency or other proceeding which remains undismissed for a period of sixty (60) days; or Borrower is adjudicated insolvent or bankrupt; or any order of relief or other order approving any such case or proceeding is entered; or Borrower suffers any appointment of any custodian, private or court appointed receiver or the like for it or any substantial part of its property which continues undischarged or unstayed for a period of sixty (60) days; or Borrower makes a general assignment for the benefit of creditors; or Borrower shall fail to pay or shall state that it is unable to pay or shall be liable to pay, its debts as they become due or by any act or failure to act expressly indicate its consent to, approval of or acquiescence in any of the foregoing; or any corporate or other action is taken by the Borrower for the purpose of effecting any of the foregoing.
  
 (b) Upon the occurrence of an Event of Default, the Lender shall give the Borrower notice of such occurrence, at which time the Borrower shall have five (5) business days from receipt of such notice to pay the outstanding amount of the Note, with any unpaid interest thereof, in full. In the event that full payment is not made upon the expiry of the five (5) day period, a default penalty equal to two percent (2%) of the Face Amount per month during the period of Default (the “Default Penalty”). Lender may then, at its sole discretion declare the entire then outstanding Face Amount of this Note together with any unpaid interest and the Default Penalty immediately due and payable (a “Default Declaration”), in which event the Lender may, at its sole discretion take any action it deems necessary to recover amounts due under this Note.
  
  	 
	2
	 
 
	 

  
 (c) Upon the occurrence of an Event of Default, the Lender shall be entitled to receive, in addition to the Face Amount of the Note, interest thereon and the Default Penalty, the Lender shall be entitled to recover all of its costs, fees (including without limitation, reasonable attorney’s fees and disbursements), and expenses relating collection and enforcement Note, including all costs and expenses incurred by it in enforcing its rights under the Note and any transaction document entered into contemporaneously herewith. 
  
 (d) The failure of Lender to exercise any of its rights hereunder in any particular instance shall not constitute a waiver of the same or of any other right in that or any subsequent instance with respect to Lender or any subsequent holder. Lender need not provide and Borrower hereby waives any presentment, demand, protest or other notice of any kind, and Lender may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available to it under applicable law. The remedies available to the Lender upon the occurrence of an Event of Default shall be cumulative. 
  
 Section 5. Notices. Any and all notices, service of process or other communications or deliveries required or permitted to be given or made pursuant to any of the provisions of this Note shall be deemed to have been duly given or made for all purposes when hand delivered or sent by certified or registered mail, return receipt requested and postage prepaid, overnight mail or courier, or via electronic mail (provided that the sender of such electronic mail does not receive a notice or message indicating that such email was unsuccessful) as follows:
  
 If to Lender, at:
  
 ______________
 ______________
 ______________
 Attn: ______________
 ______________
 Or such other address as may be given to the Borrower from time to time
  
 If to Borrower, at: 
  
 Terra Tech Corp.
 2040 Main Street, Suite 225
 Irvine, California 92614
 Attn: Derek A. Peterson
 derek@terratechcorp.com
 Or such other address as may be given to the Lender from time to time
  
 Section 6. Usury. This Note is hereby expressly limited so that in no event whatsoever, whether by reason of acceleration of maturity of the loan evidenced hereby or otherwise, shall the amount paid or agreed to be paid to the Lender hereunder for the loan, use, forbearance or detention of money exceed that permissible under applicable law. If at any time the performance of any provision of this Note or of any other agreement or instrument entered into in connection with this Note involves a payment exceeding the limit of the interest that may be validly charged for the loan, use, forbearance or detention of money under applicable law, then automatically and retroactively, ipso facto, the obligation to be performed shall be reduced to such limit, it being the specific intent of the Borrower and the Lender that all payments under this Note are to be credited first to interest as permitted by law, but not in excess of (i) the agreed rate of interest set forth herein or therein or (ii) that permitted by law, whichever is the lesser, and the balance toward the reduction of principal. The provision of this Section 6 shall never be superseded or waived and shall control every other provision of this Note and all other agreements and instruments between the Borrower and the Lender entered into in connection with this Note. To the extent permitted by applicable law, Borrower waives any right to assert the defense of usury. 
  
  	 
	3
	 
 
	 

  
 Section 7. Governing Law; Waiver of Jury Trial. This Note and the provisions hereof are to be construed according to and are governed by the laws of the State of New York, without regard to principles of conflicts of laws thereof. Borrower agrees that the New York State Supreme Court located in the County of New York, State of New York shall have exclusive jurisdiction in connection with any dispute concerning or arising out of this Note or otherwise relating to the parties’ relationship. In any action, lawsuit or proceeding brought to enforce or interpret the provisions of this Note and/or arising out of or relating to any dispute between the parties, Lender shall be entitled to recover all of its costs and expenses relating collection and enforcement of this Note (including without limitation, reasonable attorney’s fees and disbursements) in addition to any other relief to which Lender may be entitled and all costs of collection, including any legal fees associated with this Note will be paid by the Borrower. Each party agrees that any process or notice to be served or delivered in connection with any action, lawsuit or proceeding brought hereunder may be accomplished in accordance with the notice provisions set forth above or as otherwise provided by applicable law.
  
 BORROWER HEREBY WAIVES TRIAL BY JURY IN ANY ACTION, PROCEEDING, CLAIM OR COUNTERCLAIM, WHETHER IN CONTRACT OR TORT, AT LAW OR IN EQUITY, ARISING OUT OF OR IN ANY WAY RELATING TO THIS NOTE. 
  
 Section 8. Successors and Assigns. Subject to applicable securities laws, this Note and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors of Borrower and the successors and assigns of Lender. 
  
 Section 9. Amendment. This Note may be modified or amended or the provisions hereof waived only with the written consent of Lender and Borrower. 
  
 Section 10. Severability. Wherever possible, each provision of this Note shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Note shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Note.
  
 [SIGNATURE PAGE TO FOLLOW]
  
  	 
	4
	 
 
	 

  
 IN WITNESS WHEREOF, Borrower has caused this Promissory Note to be duly authorized officer and/or such individual borrower as of the date first above indicated.
  
  
  	 	Terra Tech Corp.	
	 	 	 	 
		By:		
	  
	  
	Name:	 
	 	 	Title:	 

  
  
  	 
	5Exhibit 10.1

 

EMPLOYMENT AGREEMENT

  

THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered
into as of March 7, 2019, by and between Gary H. Rabin (“Rabin”), and Immune Pharmaceuticals Inc ("Company").
Company desires to engage Rabin as President and Interim Chief Executive Officerto provide certain services to Company as more
particularly set forth in Exhibit A attached hereto and made a part hereof (the “Services”). The parties desire
to set forth, in writing, the terms and conditions concerning the engagement. Accordingly, in consideration of the mutual covenants
in this Agreement, and for other good and valuable consideration, it is agreed as follows:

 

1. Engagement and Commencement Date. Commencing on March
7, 2019 (“Commencement Date”), Company hereby engages Rabin as President and Interim Chief Executive Officer, on the
terms and conditions set forth in this Agreement. By signing this Agreement, Rabin and Company understand and agree to all of the
terms and conditions outlined herein and those that are incorporated by reference, if any.

 

2. Services of Rabin. Rabin shall render to Company all
of the Services reasonably requested by Company to the best of Rabin’s abilities. It is intended that Rabin's Services will
at all times comply in all material respects with any applicable federal, state or local laws, statutes or ordinances, and all
rules, regulations and orders required in order to render all Services provided for hereunder. The Services shall be provided subject
to the supervision and, where appropriate, approval of the Company’s Board of Directors. Rabin shall devote such time and
attention to the affairs of the Company and the provision of the Services as Rabin and the Company’s Board of Directors shall
mutually agree. Such Services may be provided in person, by telephone, by electronic communication or as otherwise reasonably necessary
for the appropriate provision of such Services.

 

3. Rules and Regulations. Rabin agrees to observe and
comply in all material respects with all of Company's policies, procedures, rules and regulations that currently exist and those
rules and regulations that are from time to time added, adopted or amended, whether temporary or permanent, regarding the rendering
of the Services by Rabin and the use of staff, office and other facilities, accounting and bookkeeping systems and other related
services, if any. Moreover, Company reserves the right to make reasonable changes to Company’s rules and regulations at any
time with prior notification to Rabin. Rabin’s continued performance of the Services for Company shall constitute his consent
and approval to such modifications.

 

4. Term. The engagement of Rabin hereunder shall commence
as of the Commencement Date and shall continue for a period of approximately three months, terminating on June 7, 2019. This Agreement
may be terminated by Company at any time for any or no reason, upon thirty (30) days’ advance written notice to Rabin, and
for cause immediately upon notice, provided that Sections 7 through 9 and Sections 11 through 15, inclusive, shall survive any
termination or expiration of this Agreement. In the event of termination of this Agreement, Company shall only be obligated to
pay Rabin through the date of termination and for Services actually rendered.

 

     

     

    

 

5. Compensation. Company shall pay Rabin for the Services
hereunder an initial retainer of $11,000 via wire transfer upon signature of this agreement. In addition Company shall pay Rabin
a Work Fee of $4,000 on each of April 7, May 7 and June 7, 2019. Separately, on a monthly basis, Rabin shall remit an invoice,
which Company shall pay within ten (10) days of receipt for all reasonably incurred out-of-pocket or associated expenses that may
result from Rabin’s rendering of Services to Company, provided that such expenses are reasonable in amount, approved in advance
in writing for any amounts greater than $250, incurred for the benefit of Company and supported by itemized accountings and expense
receipts submitted to Company prior to any reimbursement therefor.

 

6. Assignment of Services by Rabin. The Services to be
provided by Rabin hereunder are personal to Rabin and may not be assigned or delegated without the prior written consent of Company,
which may be withheld in Company’s sole and subjective discretion.

 

7. [Reserved]

 

8. Confidential Information. Rabin acknowledges that
Company has established substantial goodwill and confidential information with respect to its business.

 

(a) Character of Information. Company,
among other things, is in the business of developing drug candidates. In the course of its business, Company maintains confidential
information relating to its business, which include (i) formulations, , (ii) clinical development strategies and plans, (iii) clinical
trial information, (iv) contract manufacturing, contract research and clinical trial organization relationships, contacts and related
information, (vii) existing and future strategic plans including the potential sale or exclusive licensing of one or more of the
Company’s product candidates, (viii) computer data, processes and know-how and (ix) vendors, manufacturers and developers,
all of which is stored on various forms of media (collectively "Confidential Information"). The Confidential Information
has been compiled, assembled and developed as a result of substantial efforts and expenditures by Company. Rabin acknowledges that
the Confidential Information is not in the public domain, and Company has established and implemented policies and procedures to
restrict access to all Confidential Information to persons who have a genuine need to use Confidential Information in the course
of their association with Company. Rabin hereby acknowledges that by reason of becoming apprised of Confidential Information, no
license or any other rights whatsoever, either directly or by implication, in or to the Confidential Information are acquired by
Rabin. Subject to Section 9(b) below, Rabin agrees that all Confidential Information received by Rabin in the course of his service
for Company or made available to Rabin by Company, is the sole and exclusive property of Company.

 

(b) Exceptions. Confidential Information
shall not include any information that Rabin can demonstrate: (1) is already known to Rabin or was in Rabin’s possession
before the date of disclosure under this Agreement other than pursuant to a confidentiality obligation with the Company; (2) is
or becomes publicly known through no wrongful act of Rabin; (3) is independently developed by Rabin without reference to the Confidential
Information; (4) is required to be disclosed to comply with laws, statutes, regulations, orders and other governmental rules; or
(5) is obtained by Rabin from a third party which is not, to the knowledge of Rabin, subject to any legal restriction on its right
to use and disclose such information.

 

     

     

    

 

(c) Rabin’s Representations and
Covenants; Non-Disclosure. In reliance on Rabin’s representations, warranties and covenants, from time to time Company
may permit Rabin to have access to Confidential Information, to the extent necessary and for the sole purpose of enabling Rabin
to perform the Services to Company. Subject to Section 9(b), while associated with Company and at any time after termination of
Rabin’s Services or association with Company, Rabin represents, warrants and agrees that if Company permits Rabin to have
access to Confidential Information, Rabin will use such Confidential Information only in a fiduciary capacity for the benefit of
Company, and will not use, disclose, or disseminate, directly, or indirectly, any Confidential Information, except as required
to perform the Services. In furtherance of the foregoing, Rabin shall maintain the Confidential Information in the strictest of
confidence, will not make copies, summaries, compilations or extracts of any Confidential Information, and will not permit anyone
to have access to Confidential Information, except as authorized in writing by Company. If Rabin uses, discloses, or disseminates
or causes the use, disclosure, or dissemination of Confidential Information then Rabin shall be responsible for any and all damages
suffered by Company, including but not limited to compensatory, incidental, consequential, lost profits, statutory, nominal, punitive,
and restitutionary damages as well as any and all associated legal fees, costs and expenses.

 

(d) Non-Solicitation. During the
term of this Agreement and the one-year period following any termination or expiration of this Agreement, Rabin shall not solicit
or hire any of Company’s employees or contractors for services or for the purpose of terminating, curtailing or interfering
in any way with their relationship with Company.

 

(e) Surrender of Property. Rabin
agrees that upon termination of his engagement with Company, Rabin shall immediately return to Company all documents and property
belonging to Company, including but not limited to all Confidential Information, including Rabin’s new customer and new business
leads and referral sources, mailing lists, vendor lists and supplier lists, if any.

 

10. Consulting or Other Services for Competitors. Rabin
represents and warrants that Rabin does not presently perform, intend to perform nor will Rabin perform, during the term of the
Agreement, consulting or other services for companies whose businesses or proposed businesses involve competing businesses.

 

11. Remedies. If Rabin breaches or defaults in any of
its obligations under this Agreement, specifically including Sections 9 and 10, Rabin acknowledges that Company may be irreparably
damaged and that it would be extremely difficult and impractical to measure the resulting damages in money; accordingly, Rabin
acknowledges and agrees that Company, in addition to any other available rights or remedies, shall have the right to specific performance,
injunctive relief and any other equitable remedy for any breach or threatened breach of his obligations under this Agreement, and
Rabin waives the defense that a remedy at law or damages is adequate. The Company shall not be required to post any bond or other
security in connection with any action for equitable relief. Rabin further agrees that Company shall have the right to require
Rabin to account for and pay over to Company all compensation, profits, monies, accruals, increments or other benefits derived
or received by Rabin as the result of any transaction constituting a breach of or default under this Agreement. Each of the foregoing
rights and remedies shall be independent of the other, and shall be severally enforceable, and all of such rights and remedies
shall be in addition to, and not in lieu of, any other rights and remedies available to Company under any law or in equity.

 

     

     

    

 

12. Representations and Covenants. Rabin hereby represents
and warrants to Company that:

 

(a) No Conflict. The engagement of
Rabin hereunder and the performance by Rabin of his intended Services do not and will not require the consent, waiver or approval
of any party, do not create a breach of, constitute a default under, or violate or conflict with any contract, agreement or other
instrument or any judgment or order to which Rabin is subject, including without limitation, any outstanding restrictive covenant
or non competition agreement which would interfere with or prevent Rabin’s engagement by Company hereunder as contemplated
by the parties.

 

(b) No Consent. The execution, delivery
and performance of this Agreement by Rabin do not require the consent, waiver or approval of any party.

 

(c) No Infringement. Any materials
provided by Rabin to Company shall not infringe upon the rights of any third parties including, but not limited to, intellectual
property rights, moral rights, rights of publicity or rights of privacy.

 

(d) Third Party Assignment. In the
event any intellectual property is wholly or partially created by a third party to this Agreement, Rabin undertakes to obtain the
assignment of any and all rights in such intellectual property from such third party to Company in compliance with the terms and
conditions of this Agreement, and to provide a copy of the assignment to Company.

 

13. Indemnification. Rabin agrees to indemnify, defend
and hold harmless Company, its officers, directors, shareholders and affiliates (each, an “Indemnified Person” and
collectively the “Indemnified Persons”) from and against all claims, demands, damages, liabilities, losses, settlements,
costs and expenses arising out of or in connection with Rabin’s breach of this Agreement, breach of any representations and
warranties, gross negligence or intentional misconduct. Rabin will also reimburse Company and any other Indemnified Person for
all reasonable expenses (including reasonable fees and disbursements of legal counsel), as such expenses are incurred, in connection
with investigating, preparing to defend or defending any such action, claim, proceeding or investigation, whether or not in connection
with pending or threatened litigation in which Rabin or any other Indemnified Person is a party or target.

 

     

     

    

 

14. Work for Hire.

 

(a) Work for Hire. The Rabin expressly acknowledges and agrees
that any and all proprietary materials prepared by the Rabin under this Agreement at the direction and for the benefit of Company
shall be considered “works for hire” and the exclusive property of the Company unless otherwise specified. These items
shall include, but shall not be limited to, any and all deliverables resulting from the Rabin’s Services or contemplated
by this Agreement, all tangible results and proceeds of the Services, works in progress, records, diagrams, notes, drawings, specifications,
schematics, documents, designs, improvements, inventions, discoveries, developments, trademarks, trade secrets, customer lists,
databases, domain name, software, programs, middleware, applications, and solutions conceived, made, or discovered by the Rabin,
solely or in collaboration with others, during the Term of this Agreement relating in any manner to the Rabin’s Services.

 

(b) Additional Action to Assign Interest. To the extent such
work may not be deemed a “work for hire” under applicable law, the Rabin hereby assigns to the Company all of its right,
title, and interest in and to such work. The Rabin shall execute and deliver to the Company any instruments of transfer and take
such other action that the Company may reasonably request, including, without limitation, executing and filing, at the Company’s
expense, copyright applications, assignments, and other documents required for the protection of the Company’s rights to
such materials.

 

(c) Notice of Incorporation of Existing Work. If the Rabin intends
to integrate or incorporate any work that it previously created into any work product to be created in furtherance of its performance
of the Services, the Rabin must obtain the Company’s prior written approval of such integration or incorporation. If the
Company, in its reasonable discretion, consents, the Company is hereby granted a worldwide, royalty-free, perpetual, irrevocable
license to use, distribute, modify, publish, and otherwise exploit the incorporated items in connection with the work product developed
for the Company.

  

15. Survival. Rabin and Company agree that their obligations
under Sections 9, 10, 12 and 13 of this Agreement shall continue in effect after termination of Rabin’s engagement with Company,
regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary, and that Company
is entitled to communicate Rabin’s obligations under this Agreement to any third party. The parties’ obligations hereunder
also shall be binding upon their successors in interest, heirs, executors, assigns, and administrators and shall inure to the benefit
of the other party.

 

     

     

    

 

16. General Terms and Conditions. If either party brings
an action to enforce its rights under this Agreement, in addition to such other remedies which the court may grant, the prevailing
party shall be entitled to recover reasonable attorneys' fees and costs. As used in this Agreement, the neuter shall include the
masculine and feminine and vice versa, and the singular shall include the plural and vice versa, as the context may require. This
Agreement constitutes the entire understanding between the parties with respect to its subject matter and supersedes all prior
agreements and understandings, whether oral or in writing. This Agreement shall be governed by and interpreted under the laws of
the State of New York. Except as provided in Section 11, any dispute, claim or controversy arising out of or relating to this Agreement
or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability
of this agreement to arbitrate, shall be determined by arbitration in New York County before a neutral arbitrator reasonably acceptable
to both parties. The arbitration shall be administered by JAMS pursuant to JAMS' Streamlined Arbitration Rules and Procedures.
Judgment on the Award may be entered in any court having jurisdiction. In case one or more of the provisions contained in this
Agreement shall be deemed to be invalid, illegal or unenforceable in any respect under any applicable law, the other provisions
contained herein shall not in any way be affected or impaired thereby. This Agreement may be executed in one or more counterparts
but all of the counterparts shall constitute one agreement.

 

[Signature page follows.]

 

     

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Consulting Agreement on the day and year first set forth above.

 

	Immune Pharmaceuticals Inc (“Company”)	 
	 	 	 
	 	 	 
	Signature:	/s/ Jeff Paley	 
	 	 	 
	 	 	 
	Name:	Jeff Paley	 
	 	 	 
	Title:	Director and Chair, Compensation Committee	 
	 	 	 
	Address:	1 Bridge Plaza North, Suite 270	 
	 	Fort Lee, NJ  07024	 
	 	 	 
	 	 	 
	GARY H. RABIN, an individual	 
	 	 	 
	 	 	 
	Signature:	/s/ Gary Rabin	 
	 	 	 
	 	 	 
	Name:	Gary H. Rabin "Rabin"	 
	 	 	 
	Address:	1100 Indiana Avenue	 
	 	Venice, CA  90291	 

 

     

     

    

 

EXHIBIT “A” - Description
of Rabin’s Services & Objectives

 

Rabin shall work the Company’s, board of directors
with respect to the following:

 

(1) Developing a strategy for raising third party capital, including
the sale of exclusive license of the Company’s product candidates;

(2) Assisting in strategy and negotiation with existing creditors
and investors;

(3) Assisting in the completion of transaction-specific materials,
including without limitation, PowerPoint presentations;

(4) Assisting in the documentation and review of financing arrangements;

(5) Assisting in creation of all materials and strategies to
interface with potential investors;

(6) Consultation as it relates to Company’s shareholder
cap table;

(7) Other matters appropriate for the President and Chief Executive
of a public company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]